23 hrs ago | Forbes.com
Another Downer For Merck's Cholesterol Drugs
Why investors are right to worry that a new study could damage the company's outlook.
Yale Researchers Identify Gene's Role In Promoting Atherosclerosis
Yale University researchers have found that a single gene plays a key role in the development of atherosclerosis in mice.
Genomes In Newsweek: Futures Near and Far
As a science writer, I often find it sobering to read scientific history. Science works slowly, even though we wish it would work in nanosecond breakthroughs.
Updated May 18, 2006 Atherosclerosis A disease in which arteries become dangerously narrowed by lipid deposits.
Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
The Phase III data were presented today by Kowa, at the XV International Symposium on Atherosclerosis in Boston .
Genomas Presents Drug-Specific Genetic Determinants Of Statin Safety...
Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, announced its participation at the prestigious XV International Symposium on Atherosclerosis, a meeting held triennially by the International Atherosclerosis Society.
Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug Interaction
The data were presented today by Kowa at the XV International Symposium on Atherosclerosis in Boston .
Obesity, arthritis affects women in later years
A U.S. research team said on Tuesday it had found evidence why some plaque build-ups in arteries may lead to heart attacks and stroke while others do not.
Exercise Helps Peripheral Artery Disease
While peripheral artery disease can make walking or any other type of exercise painful, exercise is actually one of the most beneficial things that you can do to reduce the pain caused by PAD.
Nanoparticles to Target Plaque
Scientists and engineers have come up with a nanoparticle that can target and attack plaque, in the hopes of finding a treatment for atherosclerosis.
Newark Beth Israel Medical Center Hosts "Us Against Athero" to Fight the Nation's Number One Killer
Newark Beth Israel Medical Center Hosts "Us Against Athero" to Fight the Nation's Number One Killer By Newark Beth Israel Medical Center 5/27/2009 The public is invited to visit Newark Beth Israel Medical Center on Wednesday, May 27 from 8 a.m. to 4 p.m. to take a virtual tour in the Artery Explorer, a mobile motion simulator to learn about ...
Invatec Officially Launches Coronary Drug-Eluting Balloon Platform IN.PACTa Falcon At EuroPCR
Main Category: Cardiovascular / Cardiology Also Included In: Medical Devices / Diagnostics Invatec, a comprehensive innovator of interventional products, today announced the availability of its newly CE marked coronary balloon, the IN.PACT Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain.
Aspirin Lowers Stroke Risk in Peripheral Artery Disease
There haven't been enough studies to tell whether aspirin reduces the risk of heart attack and death for people with the blocked leg blood vessel condition called peripheral arterial disease, but it does cut the incidence of stroke, researchers report.
Suggestion for linkage of chromosome 1p35.2 and 3q28 to plasma...
Adiponectin is inversely associated with obesity, insulin resistance, and atherosclerosis, but little is known about the genetic pathways that regulate the plasma level of this protein.
The silent killer in your arteries
By Michael Kahn London - A United States research team said on Tuesday it had found evidence why some plaque build-ups in arteries may lead to heart attacks and stroke while others do not.
Study Sheds Light On Why Some Plaques Turn Deadly
A U.S. research team said on Tuesday it had found evidence why some plaque build-ups in arteries may lead to heart attacks and stroke while others do not.
Drug Watch: Ezetimibe Simvastatin Combination Therapy: An Update
However, the combination therapy was found to be significantly more effective than the statin alone in lowering levels of LDL cholesterol, triglycerides, and C-reactive protein.
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial ...
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS , a clinical trial designed to examine the impact of 500mg of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome event, met its primary endpoint of a reduction in Low Density ...
Why Certain Arterial Plaques Can Turn Deadly
New research at Columbia University Medical Center, however, sheds light on why so few plaques in any given individual actually cause a problem.
Resverlogix Provides Quarterly Update
Alzheimer's disease biomarker assessment to be added to the Phase 1b/2a trial TSX Exchange Symbol: RVX CALGARY, April 28 /CNW/ - Resverlogix Corp.